Gynecologic Cancers

BRCA+

Questions discussed in this category

How do you counsel premenopausal women with BRCA1 or BRCA2 mutations on the need for bilateral oopherectomy?

2 Answers available

What factors impact your decision to include bevacizumab with primary chemotherapy for patients with BRCA+ or HRD+ ovarian cancer?

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses?

4 Answers available

Which PARP inhibitor do you recommend for maintenance therapy in BRCA+ ovarian cancer after primary chemotherapy and why?

How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?

3 Answers available

How do you advise patients on duration of first line maintenance PARPi and the potential risk of MDS or AML?

Is MDS/AML risk increased with longer duration of therapy?

2 Answers available

Papers discussed in this category

The New England journal of medicine, 2018-12-27

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Lancet Oncol, 2021 Mar 18

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

N Engl J Med, 2019 Dec 19

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Lancet Oncol, 2015 Jun 23

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Related Topics in Gynecologic Cancers